Dr. Mustafa Diken received his Ph.D. in tumor immunology from Johannes Gutenberg University, Mainz and is currently serving as Deputy Director Immunotherapy Development Center at Translational Oncology Institute (TRON) and as Vice President Vaccines & Immunology at BioNTech SE. His research focuses on the development of novel cancer and infectious disease vaccines based on antigen-encoding messenger RNA (mRNA) and the elucidation of immunomodulatory mechanisms for cancer immunotherapy. His other scientific interests include assay development for preclinical evaluation of cancer vaccines. His research led to novel mRNA vaccines which are currently being tested in several clinical trials and development of an mRNA vaccine against SARS-CoV-2. Dr. Diken is also the scientific secretary of the Association for Cancer Immunotherapy (CIMT), a non-profit organization aimed at advancing cancer immunotherapy.